The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Widespread transneuronal propagation of α-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson’s disease
Open accessAbstract
Parkinson’s disease (PD) is characterized by the progressive appearance of intraneuronal Lewy aggregates, which are primarily composed of misfolded α-synuclein (α-syn). The aggregates are believed to propagate via neural pathways following a stereotypical pattern, starting in the olfactory bulb (OB) and gut. We hypothesized that injection of fibrillar α-syn into the OB of wild-type mice would recreate the sequential progression of Lewy-like pathology, while triggering olfactory deficits. We demonstrate that injected α-syn fibrils recruit endogenous α-syn into pathological aggregates that spread transneuronally over several months, initially in the olfactory network and later in distant brain regions. The seeded inclusions contain posttranslationally modified α-syn that is Thioflavin S positive, indicative of amyloid fibrils. The spreading α-syn pathology induces progressive and specific olfactory deficits. Thus, we demonstrate that propagating α-syn pathology triggered in the OB is functionally detrimental. Collectively, we have created a mouse model of prodromal PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 4×
“In both PD (Goedert, 2001; Braak et al., 2003b) and other Lewy body disorders (Beach et al., 2009), pathological α-syn inclusions progressively develop in a spatially stereotypic pattern in the brain that appears to follow neuronal connections.”
BackgroundInfluentialStages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689
Luk, K. C., Kehm, V., Carroll, J., Zhang, B., O’Brien, P., Trojanowski, J. Q., & Lee, V. M.-Y. (2012) · Science · doi:10.1126/science.1227157 · Cited by 2,563
Self-citationα-Synuclein is phosphorylated in synucleinopathy lesions
Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M. S., Shen, J., Takio, K., & Iwatsubo, T. (2002) · Nature Cell Biology · doi:10.1038/ncb748 · Cited by 2,132
The Amygdaloid Complex: Anatomy and Physiology
SAH, P., FABER, E. S. L., LOPEZ DE ARMENTIA, M., & POWER, J. (2003) · Physiological Reviews · doi:10.1152/physrev.00002.2003 · Cited by 1,745 · cited 2×
“Such misfolded α-syn is then potentially transported over long distances in axons, released into the extracellular space and taken up by neighboring cells (Dunning et al., 2012; Lamberts et al., 2014).”
BackgroundBraak, H., R�b, U., Gai, W. P., & Del Tredici, K. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-002-0808-2 · Cited by 1,683
Alpha-synuclein and neurodegenerative diseases
Goedert, M. (2001) · Nature Reviews Neuroscience · doi:10.1038/35081564 · Cited by 1,408
Paxinos and Franklin's the Mouse Brain in Stereotaxic Coordinates
Paxinos, G., & Franklin, K. B. J. (2012) · Cited by 1,267
Handbook of Olfaction and Gustation
(2003) · CRC Press eBooks · doi:10.1201/9780203911457 · Cited by 1,223
α-Synuclein strains cause distinct synucleinopathies after local and systemic administration
Peelaerts, W., Bousset, L., Van der Perren, A., Moskalyuk, A., Pulizzi, R., Giugliano, M., Van den Haute, C., Melki, R., & Baekelandt, V. (2015) · Nature · doi:10.1038/nature14547 · Cited by 1,130 · cited 1×
“During this phase, termed prodromal PD, certain nonmotor signs are evident, e.g., olfactory dysfunction, rapid eye movement sleep behavior disor- der, constipation, and other autonomic disturbances (Postuma et al., 2012; Mahlknecht et al., 2015).”
Background
Research works printed but not linked: 1
- Del Tredici, 2000, Idiopathic Parkinson’s disease: staging an α-synucleinopathy with a predictable pathoanatomy
Cited by
Kim, S., Kwon, S.-H., Kam, T.-I., Panicker, N., Karuppagounder, S. S., Lee, S., Lee, J. H., Kim, W. R., Kook, M., Foss, C. A., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.05.035 · Cited by 1,397
“These findings are consistent with prior observations that pathological a-syn levels can plateau after a-syn PFF injection (Manfredsson et al., 2018; Rey et al., 2016; Uemura et al., 2018).”
BackgroundResultSelective neuronal vulnerability in Parkinson disease
Surmeier, D. J., Obeso, J. A., & Halliday, G. M. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.178 · Cited by 1,116
α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies
Wong, Y. C., & Krainc, D. (2017) · Nature Medicine · doi:10.1038/nm.4269 · Cited by 897
Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice
Gordon, R., Albornoz, E. A., Christie, D. C., Langley, M. R., Kumar, V., Mantovani, S., Robertson, A. A. B., Butler, M. S., Rowe, D. B., O’Neill, L. A., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aah4066 · Cited by 897
Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications
Pajares, M., I. Rojo, A., Manda, G., Boscá, L., & Cuadrado, A. (2020) · Cells · doi:10.3390/cells9071687 · Cited by 779
Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases
Jucker, M., & Walker, L. C. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0238-6 · Cited by 450
Modeling Parkinson’s Disease With the Alpha-Synuclein Protein
Gómez-Benito, M., Granado, N., García-Sanz, P., Michel, A., Dumoulin, M., & Moratalla, R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00356 · Cited by 437
Uemura, N., Yagi, H., Uemura, M. T., Hatanaka, Y., Yamakado, H., & Takahashi, R. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0257-5 · Cited by 328
Henderson, M. X., Cornblath, E. J., Darwich, A., Zhang, B., Brown, H., Gathagan, R. J., Sandler, R. M., Bassett, D. S., Trojanowski, J. Q., & Lee, V. M. Y. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0457-5 · Cited by 310
Self-citationα‐synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities
Alam, P., Bousset, L., Melki, R., & Otzen, D. E. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14808 · Cited by 307
Jankovic, J., Goodman, I., Safirstein, B., Marmon, T. K., Schenk, D. B., Koller, M., Zago, W., Ness, D. K., Griffith, S. G., Grundman, M., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.1487 · Cited by 301
Polinski, N. K., Volpicelli-Daley, L. A., Sortwell, C. E., Luk, K. C., Cremades, N., Gottler, L. M., Froula, J., Duffy, M. F., Lee, V. M. Y., Martinez, T. N., et al. (2018) · Journal of Parkinson’s Disease · doi:10.3233/jpd-171248 · Cited by 288
Self-citationThe vermiform appendix impacts the risk of developing Parkinson’s disease
Killinger, B. A., Madaj, Z., Sikora, J. W., Rey, N., Haas, A. J., Vepa, Y., Lindqvist, D., Chen, H., Thomas, P. M., Brundin, P., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar5280 · Cited by 279
Self-citationPrying into the Prion Hypothesis for Parkinson's Disease
Brundin, P., & Melki, R. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.1788-16.2017 · Cited by 275
Self-citationOlfactory Dysfunction in Neurodegenerative Diseases
Marin, C., Vilas, D., Langdon, C., Alobid, I., López-Chacón, M., Haehner, A., Hummel, T., & Mullol, J. (2018) · Current Allergy and Asthma Reports · doi:10.1007/s11882-018-0796-4 · Cited by 274
The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases
Rey, N. L., Wesson, D. W., & Brundin, P. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.12.013 · Cited by 257
Self-citationBorghammer, P. (2021) · Journal of Parkinson's Disease · doi:10.3233/jpd-202481 · Cited by 259
“C) Schematic representation of published data from injection of -synuclein seeds unilaterally into a single CNS location [56, 57, 59].”
BackgroundInfluentialEndocytic vesicle rupture is a conserved mechanism of cellular invasion by amyloid proteins
Flavin, W. P., Bousset, L., Green, Z. C., Chu, Y., Skarpathiotis, S., Chaney, M. J., Kordower, J. H., Melki, R., & Campbell, E. M. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1722-x · Cited by 258
Rey, N. L., George, S., Steiner, J. A., Madaj, Z., Luk, K. C., Trojanowski, J. Q., Lee, V. M.-Y., & Brundin, P. (2018) · Acta Neuropathologica · doi:10.1007/s00401-017-1792-9 · Cited by 215
Self-citationLewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration
Duffy, M. F., Collier, T. J., Patterson, J. R., Kemp, C. J., Luk, K. C., Tansey, M. G., Paumier, K. L., Kanaan, N. M., Fischer, D. L., Polinski, N. K., et al. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1171-z · Cited by 197
Self-citationThe concept of alpha-synuclein as a prion-like protein: ten years after
Steiner, J. A., Quansah, E., & Brundin, P. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2814-1 · Cited by 183
Self-citationAbdelmotilib, H., Maltbie, T., Delic, V., Liu, Z., Hu, X., Fraser, K. B., Moehle, M. S., Stoyka, L., Anabtawi, N., Krendelchtchikova, V., et al. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.05.014 · Cited by 172
“…cortex, olfactory bulb, substantia nigra pars compacta (SNpc), or muscle, show that the fibrils induce inclusions that resemble those found in PD and LBD (Luk et al., 2012) (Masuda-Suzukake et al., 2014; Masuda-Suzukake et al., 2013; Rey et al., 2016) (Ayers et al., 2017; Paumier et al., 2015).”
BackgroundTau accelerates α-synuclein aggregation and spreading in Parkinson’s disease
Pan, L., Li, C., Meng, L., Tian, Y., He, M., Yuan, X., Zhang, G., Zhang, Z., Xiong, J., Chen, G., et al. (2022) · Brain · doi:10.1093/brain/awac171 · Cited by 154
Cell-to-Cell Transmission of Tau and α-Synuclein
Uemura, N., Uemura, M. T., Luk, K. C., Lee, V. M.-Y., & Trojanowski, J. Q. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.03.012 · Cited by 149
Self-citationMechanisms of protein toxicity in neurodegenerative diseases
Chung, C. G., Lee, H., & Lee, S. B. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2854-4 · Cited by 142
Intercellular Spread of Protein Aggregates in Neurodegenerative Disease
Davis, A. A., Leyns, C. E. G., & Holtzman, D. M. (2018) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100617-062636 · Cited by 131
Alpha-Synuclein: Mechanisms of Release and Pathology Progression in Synucleinopathies
Brás, I. C., & Outeiro, T. F. (2021) · Cells · doi:10.3390/cells10020375 · Cited by 136
Defining α-synuclein species responsible for Parkinson’s disease phenotypes in mice
Froula, J. M., Castellana-Cruz, M., Anabtawi, N. M., Camino, J. D., Chen, S. W., Thrasher, D. R., Freire, J., Yazdi, A. A., Fleming, S., Dobson, C. M., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.007743 · Cited by 129
Import and Export of Misfolded α-Synuclein
Rodriguez, L., Marano, M. M., & Tandon, A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00344 · Cited by 93
“Similarly, α-syn monomers, oligomers, and fibrils injected into the murine olfactory bulb (OB) are rapidly internalized by neurons and glia that project to central olfactory structures in the brain (Rey et al., 2013, 2016).”
BackgroundBantle, C. M., Phillips, A. T., Smeyne, R. J., Rocha, S. M., Olson, K. E., & Tjalkens, R. B. (2019) · npj Parkinson's Disease · doi:10.1038/s41531-019-0090-8 · Cited by 89
Sorrentino, Z. A., Brooks, M. M. T., Hudson, V., Rutherford, N. J., Golde, T. E., Giasson, B. I., & Chakrabarty, P. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0182-z · Cited by 79
Chemosensory dysfunction in neurodegenerative diseases
(2019) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-63855-7.00020-4 · Cited by 78
Herman, S., Djaldetti, R., Mollenhauer, B., & Offen, D. (2023) · Brain · doi:10.1093/brain/awac261 · Cited by 62
Metabolomic Profiling of Bile Acids in an Experimental Model of Prodromal Parkinson’s Disease
Graham, S. F., Rey, N. L., Ugur, Z., Yilmaz, A., Sherman, E., Maddens, M., Bahado-Singh, R. O., Becker, K., Schulz, E., Meyerdirk, L. K., et al. (2018) · Metabolites · doi:10.3390/metabo8040071 · Cited by 60
Self-citationFatty Acid Binding Protein 3 Enhances the Spreading and Toxicity of α-Synuclein in Mouse Brain
Yabuki, Y., Matsuo, K., Kawahata, I., Fukui, N., Mizobata, T., Kawata, Y., Owada, Y., Shioda, N., & Fukunaga, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062230 · Cited by 49
“Because mouse α-Syn PFF is likely easy to develop and induces greater phosphorylated α-Syn immunoreactivity than human α-Syn PFF [5,19,22,43], this may also be a reason for the different efficacies of MF1 on phosphorylated α-Syn.”
BackgroundHuntington, T. E., & Srinivasan, R. (2021) · Aging and disease · doi:10.14336/ad.2021.0517 · Cited by 34
Sokratian, A., Zhou, Y., Tatli, M., Burbidge, K. J., Xu, E., Viverette, E., Donzelli, S., Duda, A. M., Yuan, Y., Li, H., et al. (2024) · Science Advances · doi:10.1126/sciadv.adq3539 · Cited by 38
Jimenez-Ferrer, I., Bäckström, F., Dueñas-Rey, A., Jewett, M., Boza-Serrano, A., Luk, K. C., Deierborg, T., & Swanberg, M. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.10.017 · Cited by 26
Self-citationGrathwohl, S., Quansah, E., Maroof, N., Steiner, J. A., Spycher, L., Benmansour, F., Duran-Pacheco, G., Siebourg-Polster, J., Oroszlan-Szovik, K., Remy, H., et al. (2020) · doi:10.21203/rs.3.rs-100199/v1 · Cited by 17
Self-citation
Metadata
- Authors
- Rey, N. L., Steiner, J. A., Maroof, N., Luk, K. C., Madaj, Z., Trojanowski, J. Q., Lee, V. M.-Y., & Brundin, P.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2016-08-08
- Volume
- 213
- Issue
- 9
- Pages
- 1759-1778
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2507685477
- Cited by
- 388
- References
- 58
- FWCI
- 29.61
- Type
- journal article
- Language
- en
- Open access
- green
- Funders
- European Research Council (PRISTINE-PD 269064)
- Michael J. Fox Foundation
- National Institutes of Health (NIA PO1 AG 17586-10, PO1 AG-032953, NINDS P50 NS053488-02, NIA UO1 AG029213-01)
- Cure Parkinson’s Trust
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.